Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability.
The DOI matches its Crossref record.
Abstract
The effects of orally administered placebo, diphenhydramine, lorazepam, methocarbamol and placebo were studied in volunteers with histories of recreational substance abuse including sedative/hypnotics. Placebo, diphenhydramine (100, 200 and 400 mg), lorazepam (1 and 4 mg) and methocarbamol (2.25 and 9 g) were tested in a randomized, double-blind crossover study using 14 subjects. Psychomotor and cognitive performance and subject- and observer-rated responses were measured daily before and for 5.5 hr after drug administration. The results showed that each of the drugs exhibited a different profile of effects on the test battery. Lorazepam produced significant increases in subjects' ratings of drug effect and liking, increases in measures of sedation and impairment of psychomotor performance. Methocarbamol also produced significant increases in subjects' ratings of drug effect and liking and measures of sedation, but it produced only minor impairment of psychomotor and cognitive performance. Diphenhydramine increased subjects' and observers' ratings of drug effect and measures of sedation, but it produced less psychomotor performance impairment and liking than lorazepam. Diphenhydramine produced the most side effects. The present study clearly differentiated the behavioral and subjective profiles of diphenhydramine, lorazepam and methocarbamol. Consistent with its recognized low abuse liability, diphenhydramine produced fewer increases in measures of positive mood and more adverse effects. The considerable overlap in subjective effect measures of positive mood make further differentiation with respect to abuse liability difficult.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
H1-Receptor Antagonists: Comparative Tolerability and Safety
Estelle, F., & Simons, R. (1994) · Drug Safety · doi:10.2165/00002018-199410050-00002 · Cited by 751
Fischer, B. A., & Boggs, D. L. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.003 · Cited by 32
“People with a history of sedative abuse have ranked antihistamines significantly higher on ‘‘liking’’ versus placebo (Preston et al., 1992) and not significantly different from the benzodiazepine lorazepam (Mumford et al.”
BackgroundO'Donnell, K. C., Mennenga, S. E., Owens, L. T., Podrebarac, S. K., Baron, T., Rotrosen, J., Ross, S., Forcehimes, A. A., & Bogenschutz, M. P. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106976 · Cited by 23
Brutcher, R. E., Nader, S. H., & Nader, M. A. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228577 · Cited by 11
“, 2009) consistent with laboratory findings in humans (Preston et al., 1992; Mumford et al., 1996) and animals (McKearney, 1982; Bergman and Spealman, 1986, 1988; Bergman, 1990; Jun et al.”
Result
Metadata
- Authors
- Preston, K. L., Wolf, B., Guarino, J. J., & Griffiths, R. R.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1992-08
- Volume
- 262
- Issue
- 2
- Pages
- 707-720
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W1917052505
- Cited by
- 55
- References
- 0
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. https://app.cochat.ai/papers/10.1016/s0022-3565(25)10815-x
- The paper
- Preston, K. L., Wolf, B., Guarino, J. J., & Griffiths, R. R. (1992). Subjective and behavioral effects of diphenhydramine, lorazepam and methocarbamol: evaluation of abuse liability. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(25)10815-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.